Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
| Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
| CLDN18.2 CAR-T - 01 | PhaseI | Solid Tumor | Advanced refractory gastrointestinal tumors | ||
| CLDN18.2 VHH - 01 | Lead | Solid Tumor | Gastric Cancer,Pancreatic cancer |
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| Claudin18.2 mAb | Monospecific antibody | Oncology/Cancer | Gastric cancer | Phase I | Global |
| Claudin18.2×CD8+ T bsAb | Bispecific antibody | Oncology/Cancer | Gastric cancer,Pancreatic cancer,Oophoroma | IND | Global |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CL2-H85D4 | Human | Biotinylated Human Claudin-18.2 Protein, His,Avitag™&Flag Tag (Nanodisc) |  |
|
|
| CL2-H85D3 | Human | Biotinylated Human Claudin-18.2 Protein, His,Avitag™&Flag Tag (Detergent) |  |
|
|
| CAA-B002 | Mouse | Claudin18.2 IHC 3B10 Kit | |||
| HCS-S278 | Mouse | Recombinant Monoclonal Anti-Claudin-18.2 Antibody, Mouse (3B10) | |||
| CL2-H5586 | Human / Cynomolgus | Human / Cynomolgus Claudin-18.2 Protein, His,Twin-Strep Tag (Nanodisc) |  |
|
|
| CL2-M5585 | Mouse | Mouse Claudin-18.2 Protein, His,Twin-Strep Tag (Detergent) |  |
|
|
|
New
CL2-HF218
|
Human | Fluorescent Human Claudin-18.2 Full Length Protein (VLP) |
|
||
|
New
CL2-H52P7
|
Human | Human Claudin-18.2 Full Length Protein (VLP) |
|
||
| CHEK-ATP033 | Human | HEK293/Human Claudin-18.2 Stable Cell Line | |||
|
New
CL2-H5587
|
Human / Cynomolgus | Human / Cynomolgus Claudin-18.2 Protein, His,Twin-Strep Tag (Detergent) |  |
|
2e5 of Anti-Claudin-18.2 CAR-293 cells were stained with 100 μL of 3 μg/mL of Fluorescent Human Claudin-18.2 Full Length Protein-VLP (Cat. No.CL2-HF218) and negative control protein respectively, FITC signals was used to evaluate the binding activity (QC tested).
FACS assay shows that Anti-Claudin-18.2 antibody can bind to HEK293/Human Claudin-18.2 Stable Cell Line. HEK293/Human Claudin-18.2 stable cells was red line, Negative control HEK293 cells was grey line (QC tested).
Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 captured on Protein A Chip can bind Human / Cynomolgus Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-H5586) with an affinity constant of 12.6 nM as determined in SPR assay (Biacore 8K) (Routinely tested).
Claudin-18.1 Monoclonal Antibody captured on CM5 chip via anti-mouse antibodies surface can bind Mouse Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-M5585) with an affinity constant of 13 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Zolbetuximab | GC-182; iMAB-362; IMAB-362 | Approved | Ganymed | Vyloy, VYLOY | Japan | Stomach Neoplasms | Astellas Pharma Inc | 2024-03-26 | Solid tumours; Lymphangioma, Cystic; Esophageal Neoplasms; Stomach Neoplasms; Pain; Gastrointestinal Diseases; Pancreatic Neoplasms; Adenocarcinoma | Details |
| Zolbetuximab | GC-182; iMAB-362; IMAB-362 | Approved | Ganymed | Vyloy, VYLOY | Japan | Stomach Neoplasms | Astellas Pharma Inc | 2024-03-26 | Solid tumours; Lymphangioma, Cystic; Esophageal Neoplasms; Stomach Neoplasms; Pain; Gastrointestinal Diseases; Pancreatic Neoplasms; Adenocarcinoma | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Osemitamab | MSB-018; TST-001 | Phase 3 Clinical | Mabspace Biomedicine (Suzhou) Co Ltd, HJB (Hangzhou) Co Ltd | Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Lung Neoplasms; Gallbladder Neoplasms; Gastrointestinal Neoplasms | Details |
| IBI-343 | IBI-343 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms | Details |
| LM-302 | TPX-4589; LM-302 | Phase 3 Clinical | Eli Lilly Trading (Shanghai) Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Gastrointestinal Neoplasms | Details |
| SHR-A-1904 | SHR-A-1904; SHR-A1904 | Phase 3 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Pancreatic Neoplasms | Details |
| M-108 | M108; M-108 | Phase 3 Clinical | FutureGen Biopharm (Beijing) Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms | Details |
| CMG-901 | CMG-901; CMG901; AZD-0901; AZD0901 | Phase 3 Clinical | Keymed Biosciences Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms; Adenocarcinoma | Details |
| ASKB-589 | ASKB-589 | Phase 3 Clinical | Jiangsu Aosaikang Pharmaceutical Co Ltd, AskGene Pharma Inc | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
| KD-182 | KD-182 | Phase 2 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Stomach Neoplasms; Carcinoma, Pancreatic Ductal | Details |
| Recombinant humanized anti-Claudin 18.2 monoclonal antibody (CARsgen) | AB-011 | Phase 2 Clinical | Kaixing Life Technology (Shanghai) Co Ltd, Carsgen Biomedicine (Shanghai) Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| CLDN18.2-TAC T cells Therapy | CLDN-18.2-TAC T cells; CLDN18.2-TAC T cells | Phase 2 Clinical | Triumvira Immunologics Inc | Solid tumours; Stomach Neoplasms; Neoplasm Metastasis | Details |
| HBM-7022 | HBM-7022; AZD-5863 | Phase 2 Clinical | Harbour Biomed | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Digestive System Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal; Gastrointestinal Neoplasms | Details |
| XNW-27011 | XNW-27011 | Phase 2 Clinical | Suzhou Sinovent Pharmaceuticals Co Ltd | Solid tumours | Details |
| IMC-002(Suzhou Immunofoco) | IMC-002 | Phase 2 Clinical | Suzhou Immunofoco Biotechnology Co Ltd | Ovarian Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Adenocarcinoma | Details |
| PM-1032 | PM1032; PM-1032 | Phase 2 Clinical | Biotheus Inc, Shanghai Genechem Co Ltd | Neoplasms | Details |
| PT-886 | PT-886; PT886 | Phase 2 Clinical | Phanes Therapeutics Inc | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal | Details |
| ATG-022 | ATG-022 | Phase 2 Clinical | Antengene Corporation Co Ltd | Solid tumours; Stomach Neoplasms; Neoplasms; Neoplasm Metastasis | Details |
| QLS-31905 | QLS-31905 | Phase 2 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| SOT-102 | SOT-102; SOT102; SO-N102 | Phase 2 Clinical | Sotio Biotech AG | Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms | Details |
| Q-1802 | Q-1802 | Phase 2 Clinical | Qiyu Biotechnology (Shanghai) Co Ltd | Solid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms | Details |
| Recombinant humanized monoclonal antibody MIL93(Mabworks) | MIL-93 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Solid tumours; Neoplasms | Details |
| RC-118 | RC-118; YH005 ADC | Phase 2 Clinical | RemeGen Co Ltd, Biocytogen Pharmaceuticals (Beijing) Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
| Satricabtagene autoleucel | CT041; CT-041 | Phase 2 Clinical | CARsgen Therapeutics Holdings Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
| SPX-101 (Sparx Therapeutics) | KY-71113; SX-001; KY71113; SPX-101 | Phase 1 Clinical | Sparx Therapeutics Inc, Kpc Pharmaceuticals Inc | Solid tumours; Stomach Neoplasms | Details |
| IM-92 | IM-92 | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| KD-496 | KD-496(4th); KD-496 | Phase 1 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms | Details |
| Gresonitamab | AMG-910 | Phase 1 Clinical | Amgen Inc | Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma | Details |
| AZD-6422 | AZD6422; AZD-6422 | Phase 1 Clinical | Astrazeneca Plc | Gastrointestinal Neoplasms | Details |
| 68Ga-PMD22(Peking Union Medical College Hospital) | Phase 1 Clinical | Peking Union Medical College Hospital | Gastrointestinal Neoplasms | Details | |
| AK-132 | AK132; AK-132 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
| TQB-2103 | TQB2103; TQB-2103 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Neoplasms | Details |
| BIO-008 | BIO-008 | Phase 1 Clinical | Shijiazhuang Yiling Pharmaceutical Co Ltd | Solid tumours | Details |
| BA-1301 | BA-1301; BA1301 | Phase 1 Clinical | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details | |
| LB-1904 | LB-1904 | Phase 1 Clinical | Stomach Neoplasms | Details | |
| CT-048 | CT-048; KJ-C1807; KJ-C-1807 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
| ASP-2138 | ASP-2138 | Phase 1 Clinical | Astellas Pharma Global Development Inc, Xencor Inc | Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms | Details |
| LB-4330 | Bis-2; LB-4330 | Phase 1 Clinical | L&L Biopharma Co Ltd | Solid tumours | Details |
| HEC-016 | HEC-016 | Phase 1 Clinical | People Hospital Of Luohu,Shenzhen | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| PM-3023 | PM-3023 | Phase 1 Clinical | Biotheus Inc | Solid tumours | Details |
| RD-07 | RD-07 | Phase 1 Clinical | Peking University | Solid tumours | Details |
| JS-107 | JS-107; JS107 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Pancreatic Neoplasms | Details |
| TORL-2-307-ADC | TORL-2-307-ADC | Phase 1 Clinical | Torl Biotherapeutics LLC | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
| BC-008 | BC-008 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Solid tumours; Neoplasms | Details |
| BC-007 (Dragonboat Biopharmaceutical) | BC-007 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Solid tumours; Neoplasms | Details |
| DR-30303 | DR30303 | Phase 1 Clinical | Zhejiang Doer Biologics Corp | Solid tumours | Details |
| SG-1906 | SG-1906; SG1906 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Solid tumours; Neoplasms | Details |
| SKB-315 | SKB-315; SKB315 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| BA-1105 | BA-1105; BA1105 | Phase 1 Clinical | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms | Details | |
| LY-011(Shanghai Longyao) | LY-011 | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Stomach Neoplasms; Pancreatic Neoplasms | Details |
| IBI-389 | IBI-389 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| NBL-015 | NBL-015 | Phase 1 Clinical | Shanghai Xinshi Biological Medicine Co Ltd | Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| IBI-360 | IBI-360 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| SYSA-1801 | SYSA-1801; SYSA1801; CPO-102; EO-3021 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms | Details |
| Givastomig | TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-033721; TJ-CD4B/ABL111 | Phase 1 Clinical | I-Mab Biopharma Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis | Details |
| QL-1779 | QL-1779; QL1779 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| LM-102 | LM-102 | Phase 1 Clinical | LaNova Medicines Ltd | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms | Details |
| HBM-1029 | HBM-1029; HBM1029 | Phase 1 Clinical | Harbour Biomed | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms | Details |
| LCAR-C18S CAR-T cell therapy | LB-1908; LCAR-C18S; LCAR-C-18-S | Phase 1 Clinical | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms | Details | |
| CLDN18.2 UCAR-T cell therapy | CLDN18.2 UCAR-T | Clinical | Zhongshan City People'S Hospital, T-Maximum Pharmaceutical (Suzhou) Co Ltd | Stomach Neoplasms | Details |
| 124I-18B10 | 124-I-18-B-10; 124I-18B10 | Clinical | Transcenta Holding Ltd, Beijing Cancer Hospital | Gastrointestinal Neoplasms | Details |
| 89Zr-NY005 | 89Zr-NY005 | Clinical | Wuxi No 4 People'S Hospital | Solid tumours | Details |
| IBI-345 | IBI-345 | Innovent Biologics(Suzhou) Co Ltd | Details | ||
| Osemitamab | MSB-018; TST-001 | Phase 3 Clinical | Mabspace Biomedicine (Suzhou) Co Ltd, HJB (Hangzhou) Co Ltd | Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Lung Neoplasms; Gallbladder Neoplasms; Gastrointestinal Neoplasms | Details |
| IBI-343 | IBI-343 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms | Details |
| LM-302 | TPX-4589; LM-302 | Phase 3 Clinical | Eli Lilly Trading (Shanghai) Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Gastrointestinal Neoplasms | Details |
| SHR-A-1904 | SHR-A-1904; SHR-A1904 | Phase 3 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Pancreatic Neoplasms | Details |
| M-108 | M108; M-108 | Phase 3 Clinical | FutureGen Biopharm (Beijing) Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms | Details |
| CMG-901 | CMG-901; CMG901; AZD-0901; AZD0901 | Phase 3 Clinical | Keymed Biosciences Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms; Adenocarcinoma | Details |
| ASKB-589 | ASKB-589 | Phase 3 Clinical | Jiangsu Aosaikang Pharmaceutical Co Ltd, AskGene Pharma Inc | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
| KD-182 | KD-182 | Phase 2 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Stomach Neoplasms; Carcinoma, Pancreatic Ductal | Details |
| Recombinant humanized anti-Claudin 18.2 monoclonal antibody (CARsgen) | AB-011 | Phase 2 Clinical | Kaixing Life Technology (Shanghai) Co Ltd, Carsgen Biomedicine (Shanghai) Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| CLDN18.2-TAC T cells Therapy | CLDN-18.2-TAC T cells; CLDN18.2-TAC T cells | Phase 2 Clinical | Triumvira Immunologics Inc | Solid tumours; Stomach Neoplasms; Neoplasm Metastasis | Details |
| HBM-7022 | HBM-7022; AZD-5863 | Phase 2 Clinical | Harbour Biomed | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Digestive System Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal; Gastrointestinal Neoplasms | Details |
| XNW-27011 | XNW-27011 | Phase 2 Clinical | Suzhou Sinovent Pharmaceuticals Co Ltd | Solid tumours | Details |
| IMC-002(Suzhou Immunofoco) | IMC-002 | Phase 2 Clinical | Suzhou Immunofoco Biotechnology Co Ltd | Ovarian Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Adenocarcinoma | Details |
| PM-1032 | PM1032; PM-1032 | Phase 2 Clinical | Biotheus Inc, Shanghai Genechem Co Ltd | Neoplasms | Details |
| PT-886 | PT-886; PT886 | Phase 2 Clinical | Phanes Therapeutics Inc | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal | Details |
| ATG-022 | ATG-022 | Phase 2 Clinical | Antengene Corporation Co Ltd | Solid tumours; Stomach Neoplasms; Neoplasms; Neoplasm Metastasis | Details |
| QLS-31905 | QLS-31905 | Phase 2 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| SOT-102 | SOT-102; SOT102; SO-N102 | Phase 2 Clinical | Sotio Biotech AG | Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms | Details |
| Q-1802 | Q-1802 | Phase 2 Clinical | Qiyu Biotechnology (Shanghai) Co Ltd | Solid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms | Details |
| Recombinant humanized monoclonal antibody MIL93(Mabworks) | MIL-93 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Solid tumours; Neoplasms | Details |
| RC-118 | RC-118; YH005 ADC | Phase 2 Clinical | RemeGen Co Ltd, Biocytogen Pharmaceuticals (Beijing) Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
| Satricabtagene autoleucel | CT041; CT-041 | Phase 2 Clinical | CARsgen Therapeutics Holdings Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
| SPX-101 (Sparx Therapeutics) | KY-71113; SX-001; KY71113; SPX-101 | Phase 1 Clinical | Sparx Therapeutics Inc, Kpc Pharmaceuticals Inc | Solid tumours; Stomach Neoplasms | Details |
| IM-92 | IM-92 | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| KD-496 | KD-496(4th); KD-496 | Phase 1 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms | Details |
| Gresonitamab | AMG-910 | Phase 1 Clinical | Amgen Inc | Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma | Details |
| AZD-6422 | AZD6422; AZD-6422 | Phase 1 Clinical | Astrazeneca Plc | Gastrointestinal Neoplasms | Details |
| 68Ga-PMD22(Peking Union Medical College Hospital) | Phase 1 Clinical | Peking Union Medical College Hospital | Gastrointestinal Neoplasms | Details | |
| AK-132 | AK132; AK-132 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
| TQB-2103 | TQB2103; TQB-2103 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Neoplasms | Details |
| BIO-008 | BIO-008 | Phase 1 Clinical | Shijiazhuang Yiling Pharmaceutical Co Ltd | Solid tumours | Details |
| BA-1301 | BA-1301; BA1301 | Phase 1 Clinical | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details | |
| LB-1904 | LB-1904 | Phase 1 Clinical | Stomach Neoplasms | Details | |
| CT-048 | CT-048; KJ-C1807; KJ-C-1807 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
| ASP-2138 | ASP-2138 | Phase 1 Clinical | Astellas Pharma Global Development Inc, Xencor Inc | Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms | Details |
| LB-4330 | Bis-2; LB-4330 | Phase 1 Clinical | L&L Biopharma Co Ltd | Solid tumours | Details |
| HEC-016 | HEC-016 | Phase 1 Clinical | People Hospital Of Luohu,Shenzhen | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| PM-3023 | PM-3023 | Phase 1 Clinical | Biotheus Inc | Solid tumours | Details |
| RD-07 | RD-07 | Phase 1 Clinical | Peking University | Solid tumours | Details |
| JS-107 | JS-107; JS107 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Pancreatic Neoplasms | Details |
| TORL-2-307-ADC | TORL-2-307-ADC | Phase 1 Clinical | Torl Biotherapeutics LLC | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
| BC-008 | BC-008 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Solid tumours; Neoplasms | Details |
| BC-007 (Dragonboat Biopharmaceutical) | BC-007 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Solid tumours; Neoplasms | Details |
| DR-30303 | DR30303 | Phase 1 Clinical | Zhejiang Doer Biologics Corp | Solid tumours | Details |
| SG-1906 | SG-1906; SG1906 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Solid tumours; Neoplasms | Details |
| SKB-315 | SKB-315; SKB315 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| BA-1105 | BA-1105; BA1105 | Phase 1 Clinical | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms | Details | |
| LY-011(Shanghai Longyao) | LY-011 | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Stomach Neoplasms; Pancreatic Neoplasms | Details |
| IBI-389 | IBI-389 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| NBL-015 | NBL-015 | Phase 1 Clinical | Shanghai Xinshi Biological Medicine Co Ltd | Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| IBI-360 | IBI-360 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| SYSA-1801 | SYSA-1801; SYSA1801; CPO-102; EO-3021 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms | Details |
| Givastomig | TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-033721; TJ-CD4B/ABL111 | Phase 1 Clinical | I-Mab Biopharma Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis | Details |
| QL-1779 | QL-1779; QL1779 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| LM-102 | LM-102 | Phase 1 Clinical | LaNova Medicines Ltd | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms | Details |
| HBM-1029 | HBM-1029; HBM1029 | Phase 1 Clinical | Harbour Biomed | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms | Details |
| LCAR-C18S CAR-T cell therapy | LB-1908; LCAR-C18S; LCAR-C-18-S | Phase 1 Clinical | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms | Details | |
| CLDN18.2 UCAR-T cell therapy | CLDN18.2 UCAR-T | Clinical | Zhongshan City People'S Hospital, T-Maximum Pharmaceutical (Suzhou) Co Ltd | Stomach Neoplasms | Details |
| 124I-18B10 | 124-I-18-B-10; 124I-18B10 | Clinical | Transcenta Holding Ltd, Beijing Cancer Hospital | Gastrointestinal Neoplasms | Details |
| 89Zr-NY005 | 89Zr-NY005 | Clinical | Wuxi No 4 People'S Hospital | Solid tumours | Details |
| IBI-345 | IBI-345 | Innovent Biologics(Suzhou) Co Ltd | Details |
This web search service is supported by Google Inc.
A-Z
